13F reference period
Q2 2026
Security Snapshot
Biodexa Pharmaceuticals Plc - American Depositary Shares, each representing four hundred ordinary shares (BDRX) Institutional Ownership
CUSIP: 59564R872
13F Institutional Holders and Ownership History from Q1 2026 to Q3 2026
Institutions Reporting
7
Shares (Excl. Options)
16.57K
Full value: 16,566 · shares · 30 Jun 2026Price
$2.91
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / American Depositary Shares, each representing four hundred ordinary shares
- Symbol
- BDRX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 16,566
- Total 13F value
- $48,055
- Portfolio coverage rank
- 0%
- Share change
- +15,926
- Value change
- +$46,347
- Number of holders
- 7
- Shares outstanding
- 261,922
- SEC-reported price per share
- $0.35
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- BDRX - Biodexa Pharmaceuticals Plc - American Depositary Shares, each representing four hundred ordinary shares is tracked under CUSIP 59564R872.
- 7 institutions reported positions in Q2 2026.
- 1 significant owner is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 1 to 7 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $93 to .
$48.06K
Full value: $48,055 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 7 institutions filings for Q2 2026.
Security key
59564R872
13F reference period
Q2 2026
13F holders
7
13D/G owners
1
CIK / CUSIP context first
Open Q2 2026 holders
BDRX full holder history
Biodexa Pharmaceuticals Plc SEC filings
Biodexa Pharmaceuticals Plc company facts
Biodexa Pharmaceuticals Plc insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 59564R872:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
1
Security
BDRX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 10% | $60,443 | 26,166 | Armistice Capital, LLC | 30 Jun 2026 |
As of 30 Jun 2026,
7
institutional investors reported holding
shares of
Biodexa Pharmaceuticals Plc - American Depositary Shares, each representing four hundred ordinary shares (BDRX).
This represents
6.3%
of the company’s total
outstanding shares.
16.57K
Full value: 16,566 · shares · 30 Jun 2026261.92K
Full value: 261,922 · shares · Stored outstanding share countQuarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
3
Headline period
Q2 2026
Rows shown
1-3 of 3